Evaluation of the onset of protection induced by a modified-live virus vaccine in calves challenge inoculated with type 1b bovine viral diarrhea virus

American Journal of Veterinary Research

Volumn 73, Issue 4, 2012, Pages 567-574

  Palomares, Roberto A ^a   Daniel Givens, M ^a   Wright, James C ^a   Walz, Paul H ^a   Brock, Kenny V ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MODIFIED LIVE BOVINE VIRAL DIARRHEA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BOVINE VIRAL DIARRHEA; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FEMALE; HYPERTHERMIA; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NONHUMAN; NOSE SMEAR; RANDOMIZED CONTROLLED TRIAL; RECTUM TEMPERATURE; VACCINATION; VIREMIA; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; BOVINE VIRUS DIARRHEA-MUCOSAL DISEASE; CATTLE; DIARRHEA VIRUS 1, BOVINE VIRAL; FEMALE; IMMUNIZATION SCHEDULE; MALE; VACCINES, ATTENUATED; VIRAL VACCINES;

ANIMALIA; BOVINE VIRAL DIARRHEA VIRUS 1;

EID: 84859117147     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.4.567     Document Type: Article

References (23)

1. Baker JC. The clinical manifestation of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 1995;11:425-445.
2. Houe H. Epidemiological features and economical importance of bovine virus diarrhoea virus (BVDV) infections. Vet Microbiol 1999;64:89-107.
3. Fulton RW, Briggs RE, Ridpath JF, et al. Transmission of bovine viral diarrhea virus 1b to susceptible and vaccinated calves by exposure to persistently infected calves. Can J Vet Res 2005;69:161-169.
4. Makoschey B, Janssen MGJ, Vrijenhoek MP, et al. An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2. Vaccine 2001;19:3261-3268.
5. Kelling CL, Grotelueschen DM, Smith DR, et al. Testing and management strategies for effective beef and dairy herd BVDV biosecurity programs. Bovine Pract 2000;34(1):13-21.
6. Brock KV. Strategies for the control and prevention of bovine viral diarrhea virus. Vet Clin North Am Food Anim Pract 2004;20:171-180.
7. Reber AJ, Tanner M, Okinaga T, et al. Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines. Comp Immunol Microbiol Infect Dis 2006;29:61-77.
8. Brock KV, Widel P, Walz P, et al. Onset of protection from experimental infection with type 2 bovine viral diarrhea virus following vaccination with a modified-live vaccine. Vet Ther 2007;8:88-96.
9. Fulton RW, Ridpath JF, Confer AW, et al. Bovine viral diarrhoea virus antigenic diversity: impact on disease and vaccination programmes. Biologicals 2003;31:89-95.
10. Fulton RW, Ridpath JF, Ore S, et al. Bovine viral diarrhoea virus (BVDV) subgenotypes in diagnostic laboratory accessions: distribution of BVDV1a, 1b, and 2a subgenotypes. Vet Microbiol 2005;111:35-40.
11. Lee KM, Gillespie JH. Propagation of virus diarrhea virus of cattle in tissue culture. Am J Vet Res 1957;18:952-953.
12. Clifford JR. Standard reference preparations, test reagents, and seed cultures for laboratory test reagents. Department of Veterinary Services memorandum No. 800.97. Fort Collins, Colo: USDA APHIS Veterinary Services, 2006.
13. O'Connor AM, Sargeant JM, Gardner IA, et al. The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety. J Swine Health Prod 2010;18:18-26.
14. Liebler-Tenorio EM, Ridpath JE, Neill JD. Distribution of viral antigen and tissue lesions in persistent and acute infection with the homologous strain of noncytopathic bovine viral diarrhea virus. J Vet Diagn Invest 2004;16:388-396.
15. Stoffregen B, Bolin SR, Ridpath JF, et al. Morphologic lesions in type 2 BVDV infections experimentally induced by strain BVDV2-1373 recovered from a field case. Vet Microbiol 2000;77:157-162.
16. Ridpath JF, Bendfeldt S, Neill JD, et al. Lymphocytopathogenic activity in vitro correlates with high virulence in vivo for BVDV type 2 strains: criteria for a third biotype of BVDV. Virus Res 2006;118:62-69.
17. Kelling CL, Hunsaker BD, Steffen DJ, et al. Characterization of protection against systemic infection and disease from experimental bovine viral diarrhea virus type 2 infection by use of a modified-live noncytopathic type 1 vaccine in calves. Am J Vet Res 2007;68:788-796.
18. Ridpath JF, Neill JD, Peterhans E. Impact of variation in acute virulence of BVDV1 strains on design of better vaccine efficacy challenge models. Vaccine 2007;25:8058-8066.
19. Fulton RW, Johnson BJ, Briggs RE, et al. Challenge with bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in nonvaccinated acutely infected calves. Can J Vet Res 2006;70:121-127.
20. Bolin SR, Ridpath JF. Specificity of neutralizing and precipitating antibodies induced in healthy calves by monovalent modified-live bovine viral diarrhea virus vaccines. Am J Vet Res 1989;50:817-821.
21. Janeway CA, Travers P, Walport M, et al. Adaptive immunity to infection. In: Janeway CA, Travers P, Walport M, et al, eds. Immunobiology: the immune system in health and disease. 6th ed. New York: Taylor and Francis Group, 2005;409-459.
22. Chase CC, Elmowalid G, Yousif AA. The immune response to bovine viral diarrhea virus: a constantly changing picture. Vet Clin North Am Food Anim Pract 2004;20:95-114.
23. Lenschow DJ, Lai C, Frias-Staheli N, et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 2007;104:1371-1376